Label: KETOMED- ketoprofen injection, solution

  • NDC Code(s): 61133-4007-1, 61133-4007-2
  • Packager: Bimeda, Inc.
  • Category: PRESCRIPTION ANIMAL DRUG LABEL

Drug Label Information

Updated January 6, 2022

If you are a healthcare professional or from the pharmaceutical industry please visit this version.

  • SPL UNCLASSIFIED SECTION

    KetoMedTM
    (ketoprofen)

    Sterile Solution, 100 mg/mL

    For intravenous use in horses only.

  • SPL UNCLASSIFIED SECTION

    CAUTION

    Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • DESCRIPTION

    DESCRIPTION

    Ketoprofen is a non-steroidal anti-inflammatory agent of the propionic acid class that includes ibuprofen, naproxen, and fenoprofen.  Each mL of KetoMed (ketoprofen) contains 100 mg of ketoprofen in an aqueous formulation containing: L-Arginine, 70 mg; citric acid (to adjust pH); benzyl alcohol, 0.025 g (as preservative).

    It is packaged in a multiple dose bottle.

  • ANIMAL PHARMACOLOGY & OR TOXICOLOGY

    PHARMACOLOGY

    KetoMed is a non-narcotic, non-steroidal anti-inflammatory agent with analgesic and antipyretic properties.

    In horses, intravenous dosages of ketoprofen ranging from 0.5 to 1.5 mg/lb resulted in dosage dependent anti-inflammatory effects in the chronic adjuvant carpitis model as depicted in the following graph.

    MAXIMUM FLEXION

    (intravenous ketoprofen, mean ± sem, n = 4)*

    image description

    *sem = standard error of the mean

    n = number of animals

    Additional studies using the same model in horses have shown that the effects of ketoprofen are maximal by 12 hours and still measurable at 24 hours after each dosage as depicted in the following graph.

    MAXIMUM FLEXION

    (mean ± sem, n = 6)*

    image description

    *sem = standard error of the mean

    n = number of animals

    TOXICITY

    Horses were found to tolerate ketoprofen given intravenously at dosages of 0, 1, 3 and 5 mg/lb once daily for 15 consecutive days (up to five times the recommended dosage for three times the usual duration) with no evidence of toxic effects. In clinical studies, intravenous injection of 1 mg/lb/day for five days resulted in no injection site irritation or other side effects.

    At 15-fold overdose (15 mg/lb/day) for five days one of two horses developed severe laminitis, but no gross lesions or histologic changes were observed. The toxic effects observed in the horses given a 25-fold overdose (25 mg/lb/day) for five days included inappetence, depression, icterus, abdominal swelling and postmortem findings of gastritis, nephritis and hepatitis.

  • INDICATIONS & USAGE

    INDICATION

    KetoMed(ketoprofen) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

  • DOSAGE & ADMINISTRATION

    DOSAGE AND ADMINISTRATION

    The recommended dosage is 1 mg/lb (1 mL/100 lbs) of body weight once daily. Treatment is administered by intravenous injection and may be repeated for up to five days. Onset of activity is within two hours with peak response by 12 hours. 

  • CONTRAINDICATIONS

    CONTRAINDICATIONS

    There are no known contraindications to this drug when used as directed. Intra-arterial injection should be avoided. Do not use in a horse if it has previously shown hypersensitivity to ketoprofen.

  • SPL UNCLASSIFIED SECTION

    CAUTION

    This product should not be used in breeding animals since the effects of KetoMed on fertility, pregnancy or fetal health in horses have not been determined.

  • PRECAUTIONS

    PRECAUTIONS

    Studies to determine activity of KetoMed when administered concomitantly with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring
    adjunctive therapy.

  • WARNINGS

    WARNING

    Do not use in horses intended for human consumption.

  • SPL UNCLASSIFIED SECTION

    SIDE EFFECTS

    During investigational studies, no significant side effects were reported.

  • SPL UNCLASSIFIED SECTION

    To report suspected adverse drug events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

  • HOW SUPPLIED

    HOW SUPPLIED

    KetoMed (ketoprofen) Solution 100 mg/mL is available in 50 mL and 100 mL multidose bottles.

  • STORAGE AND HANDLING

    Store at 20°C - 25°C (68°F- 77°F); excursions permitted between 15°C - 30°C (59°F - 86°F). Do not freeze.

    Use within 28 days of first puncture.

  • SPL UNCLASSIFIED SECTION

    Approved by FDA under ANADA # 200-625

    Manufactured for:
    Bimeda, Inc.

    Le Sueur, MN 56058

    www.bimeda.com


    12/20

  • PRINCIPAL DISPLAY PANEL

    image description

    image description

    image description

  • INGREDIENTS AND APPEARANCE
    KETOMED 
    ketoprofen injection, solution
    Product Information
    Product TypePRESCRIPTION ANIMAL DRUGItem Code (Source)NDC:61133-4007
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    KETOPROFEN (UNII: 90Y4QC304K) (KETOPROFEN - UNII:90Y4QC304K) KETOPROFEN100 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    ARGININE (UNII: 94ZLA3W45F) 70 mg  in 1 mL
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
    BENZYL ALCOHOL (UNII: LKG8494WBH)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:61133-4007-150 mL in 1 BOTTLE
    2NDC:61133-4007-2100 mL in 1 BOTTLE
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANADAANADA20062502/08/2021
    Labeler - Bimeda, Inc. (060492923)
    Establishment
    NameAddressID/FEIBusiness Operations
    Bimeda- MTC256232216manufacture
    Establishment
    NameAddressID/FEIBusiness Operations
    EUROAPI Germany GmbH343459891api manufacture